Vaccines based on tumour‐specific antigens are a promising approach for immunotherapy.
However, the clinical efficacy of tumour‐specific antigens is still challenging. Twelve …

Background Considering the narrow immune response spectrum of a single epitope, and
the nanoparticles (NPs) as a novel adjuvant can achieve efficient delivery of antigenic …

Integrating peptide epitopes in self-assembling materials is a successful strategy to obtain
nanovaccines with high antigen density and improved efficacy. In this study, self-assembling …

Peptide vaccines are used in clinical cancer immunotherapy, however, they generally suffer
from suboptimal immunogenicity compared to live or inactive virus vector vaccines or …

Researches on tumor-associated antigen have become a hot target in immunotherapy, but it
stagnated in the pre-clinical/clinical stages. Here, we developed a series of MAGE-A1 …

Cancer vaccines designed to initiate or amplify tumor-specific T-cell responses have been
used as a key approach for effective cancer immunotherapy. Across the history of tumor …

Background Cancer vaccines are a promising strategy for cancer immunotherapy. Cancer
vaccines elicits a specific cytotoxic immune response to tumor antigens. However, the …

Peptide vaccines are broadly used as alternatives to traditional vaccines for cancer
immunotherapy; however, the clinical translation of peptide vaccination is still limited by the …

Vaccination can provide a safe alternative to chemotherapy by using the body's natural
defense mechanisms to create a potent immune response against tumor cells. Peptide …

The aim of the present study was to improve the immunogenicity of peptide epitope vaccines
using novel nanocarriers based on self-assembling materials. Several studies demonstrated …